{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:03:07Z","timestamp":1792735387559,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.autrev.2024.103533","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T10:38:58Z","timestamp":1711103938000},"page":"103533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus"],"prefix":"10.1016","volume":"23","author":[{"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Benedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Claudio","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Variola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Zenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103533_bb0005","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0010","first-page":"jjad108","article-title":"ECCO guidelines on Extraintestinal manifestations in inflammatory bowel disease","volume":"23","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0015","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: asystematic review and Meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0020","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103533_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.autrev.2013.06.006","article-title":"Rheumatic manifestations in inflammatory bowel disease","volume":"13","author":"Atzeni","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103533_bb0030","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0035","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","article-title":"Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","volume":"13","author":"Olivieri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103533_bb0040","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.dld.2017.06.004","article-title":"Italian SpA-IBD expert panel group. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: a Delphi consensus among Italian experts","volume":"49","author":"Armuzzi","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41584-023-00984-8","article-title":"Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies","volume":"19","author":"Cozzi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0050","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.dld.2022.01.123","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology","volume":"54","author":"Bonovas","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.dld.2023.02.019","article-title":"Use of biologics for the management of Crohn\u2019s disease: IG-IBD technical review based on the GRADE methodology","volume":"55","author":"Bonovas","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0065","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.dld.2023.01.155","article-title":"Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); working panel; review panel. Use of biologics for the management of Crohn\u2019s disease: IG-IBD clinical guidelines based on the GRADE methodology","volume":"55","author":"Macaluso","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0070","series-title":"A GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1016\/j.autrev.2024.103533_bb0075","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: abidirectional 2-sample Mendelian randomization study","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2024.103533_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12874-019-0886-6","article-title":"A modified Delphi study to identify the features of high-quality measurement plans for healthcare improvement projects","volume":"20","author":"Woodcock","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2024.103533_bb0090","first-page":"45","article-title":"Achieving consensus on diagnostic criteria in rare diseases: a Pseudo-Delphi study","volume":"10","author":"Johnson","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0095","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11739-023-03238-3","article-title":"Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy\u2014a Delphi consensus","volume":"18","author":"Scarpa","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103533_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: asystematic review","volume":"6","author":"Boulkedid","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103533_bb0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.autrev.2024.103533_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.autrev.2024.103533_bb0120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2024.103533_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"ECCO 3rd European evidence-based consensus on the diagnosis and Management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/cei.13246","article-title":"Italian SpA-IBD Expert Panel Group. Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis","volume":"196","author":"Felice","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2024.103533_bb0150","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: asystematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2024.103533_bb0155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ecco-jcc\/jjz205","article-title":"Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: asystematic review","volume":"14","author":"Fauny","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000239","article-title":"Subclinical gut inflammation in ankylosing spondylitis","volume":"28","author":"Ciccia","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"77","key":"10.1016\/j.autrev.2024.103533_bb0170","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0175","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3899\/jrheum.210075","article-title":"Performance of 3 composite measures for disease activity in peripheral spondyloarthritis","volume":"49","author":"Beckers","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2024.103533_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0200","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/ibd\/izy264","article-title":"The PROSIT cohort of infliximab biosimilar in IBD: aprolonged follow-up on the effectiveness and safety across Italy","volume":"25","author":"Armuzzi","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0215","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ibd\/izaa036","article-title":"The SPOSIB SB2 Sicilian cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches","volume":"27","author":"Macaluso","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0220","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1111\/jgh.15590","article-title":"SPOSAB ABP 501: a sicilian prospective observational study of patients with inflammatory bowel disease treated with adalimumab biosimilar ABP 501","volume":"36","author":"Macaluso","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0225","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2024.103533_bb0230","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohn\u2019s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103533_bb0235","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0240","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"Van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2024.103533_bb0250","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2024.103533_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004800.pub3","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2024.103533_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004524.pub4","article-title":"Methotrexate for ankylosing spondylitis","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2024.103533_bb0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo- controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0270","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2024.103533_bb0275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in Vigibase","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2024.103533_bb0285","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40261-019-00803-7","article-title":"Inflammatory bowel disease onset during Secukinumab treatment: real concern or just an expression of dysregulated immune response?","volume":"39","author":"Fries","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.autrev.2024.103533_bb0290","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2024.103533_bb0295","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaad.2018.06.024","article-title":"Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and Ixekizumab: postmarketing analysis from the RADAR (\u201cresearch on adverse drug events and reports\u201d) program","volume":"79","author":"Orrell","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0300","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/keaa353","article-title":"Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort","volume":"60","author":"Hirano","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103533_bb0310","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0320","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0330","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0340","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s Study Group Investigators","volume":"34","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3899\/jrheum.220315","article-title":"Management of peripheral arthritis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Leung","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103533_bb0350","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.gastro.2016.02.085","article-title":"The METEOR trial: the burial of methotrexate in ulcerative colitis?","volume":"151","author":"Macaluso","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2024.103533_bb0355","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s40265-022-01750-y","article-title":"Spondyloarthropathy in inflammatory bowel disease: from pathophysiology to pharmacological targets","volume":"82","author":"Crispino","year":"2022","journal-title":"Drugs."},{"key":"10.1016\/j.autrev.2024.103533_bb0360","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0365","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0370","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0375","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0380","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0385","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0390","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.autrev.2024.103533_bb0395","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/ GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0400","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/ GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0405","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2024.103533_bb0410","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0415","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103533_bb0420","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2024.103533_bb0425","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2024.103533_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0435","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2024.103533_bb0440","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.dld.2018.02.013","article-title":"The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases","volume":"50","author":"Macaluso","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0445","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103533_bb0450","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/rheumatology\/kez056","article-title":"Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Alivernini","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103533_bb0455","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103533_bb0460","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","article-title":"Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab","volume":"59","author":"Dupr\u00e9","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103533_bb0465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Groupe D\u2019etudes Th\u00e9rapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2024.103533_bb0470","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T13:30:07Z","timestamp":1717335007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1568997224000247"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103533","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103533"}}